PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 15 | 1 | 32-40
Article title

Poziom współpracy pacjentów chorych na schizofrenię w zakresie przyjmowania leków a ryzyko nawrotu psychozy

Content
Title variants
EN
The level of medication adherence in schizophrenic patients and the risk of psychotic relapse
Languages of publication
PL
Abstracts
EN
Schizophrenia is a chronic disease with a high risk of relapse. Modern treatment of schizophrenia that involves pharmacotherapy as its vital element may reduce this risk. However, effective pharmacological intervention requires patient’s compliance with a treatment regimen. This paper provides an overview of the available literature on possible associations between the level of medication adherence in schizophrenic patients and the risk of psychotic relapse and psychiatric rehospitalization. In the first part, the article offers general information on basic concepts, prevalence data and possible factors contributing to nonadherence in schizophrenia. The studies published to date have shown the significant relationship between a level of collaboration with drug treatment by schizophrenic patients and the risk of relapse and rehospitalization. This relationship is complex and largely determined by factors indirectly connected to both the level of medication adherence and the relapse risk.
PL
Schizofrenia jest przewlekłą chorobą obarczoną wysokim ryzykiem nawrotu. Nowoczesne leczenie schizofrenii, którego istotnym składnikiem jest farmakoterapia może w znacznym stopniu zmniejszyć to ryzyko. Jednak aby leczenie farmakologiczne było skuteczne, konieczna jest dobra współpraca w zakresie wypełniania zaleceń lekarskich ze strony pacjenta. W artykule tym dokonano przeglądu dostępnej literatury dotyczącej powiązań pomiędzy poziomem współpracy w zakresie przyjmowania leków przez pacjentów chorych na schizofrenię a ryzykiem nawrotu psychozy i ponownej hospitalizacji psychiatrycznej. Wychodząc od podstawowych definicji i rozpowszechnienia problemu niestosowania się do zaleceń lekarskich w tej grupie pacjentów, poprzez ukazanie czynników ryzyka wystąpienia tego zjawiska, opisano możliwe powiązania pomiędzy poziomem współpracy pacjentów w zakresie przyjmowania leków a ryzykiem nawrotu psychozy. Dotychczasowe badania wskazują na obecność istotnej zależności pomiędzy poziomem współpracy w zakresie przyjmowania leków przez pacjentów a ryzykiem nawrotu psychozy i rehospitalizacji. Związek ten ma charakter złożony, a duże znaczenie odgrywają czynniki pośrednio związane zarówno z poziomem współpracy przy leczeniu jak i ryzykiem nawrotu schizofrenii.
Discipline
Year
Volume
15
Issue
1
Pages
32-40
Physical description
Dates
published
2014
References
  • 1. Barkhof E., Meijer CJ., Sonneville LMJ., Linszen D.H., Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia – a review of the past decade. Eur. Psychiatry, 2012; 27(1): 9–18.
  • 2. San L., Ciudad A., Alvarez E., Bobes J., Gilaberte I. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry, 2007; 22: 490–498.
  • 3. Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr., 2006; 11: 1–7.
  • 4. Weiden PJ., Kozma C., Grogg A., Locker J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv., 2004; 55: 886–891.
  • 5. Masand PS., Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol., 2006; 1: 47–56.
  • 6. Bodén R., Brandt L., Kieler H., Andersen M., Reutfors J.Early non- adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophr. Res., 2011; 133(1-3): 36–41.
  • 7. Friemann K., Wciórka J. Compliance– przeżytek czy termin użyteczny. Postępy Psychiatr. Neurol., 2008; 17(4): 365–375.
  • 8. Urquhart J.Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 1996; 17: 8–15.
  • 9. Horne R. Compliance, adherence, and concordance. Implications for asthma treatment. Chest, 2006; 130: 65–72.
  • 10. Heath I.A wolf in sheep’s clothing: a critical look at the ethics of drug taking. BMJ, 2003; 327: 856–858.
  • 11. Chatterjee JS. From compliance to concordance in diabetes. J. Med. Ethics, 2006; 32(9): 507–510.
  • 12. Royal Pharmaceutical Society of Great Britain. From compliance to concordance: achieving shared goals in medicine taking. London; RPS: 1997.
  • 13. Dickinson D., Wilkie P., Harris M.Taking medicines: concordance is not compliance. BMJ, 1999; 319(7212): 787.
  • 14. Charles C., Gafni A., Whelan T.Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc. Sci. Med., 1997; 44: 681–692.
  • 15. Kane JM. Problems of compliance in the outpatient treatment of schizophrenia. J. Clin. Psychiatry, 1983; 44: 3–6.
  • 16. Oehl M., Hummer M., Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr. Scand. Suppl., 2000; 407: 83–86.
  • 17. Haynes RB., Taylor DW., Sackett DL. Compliance in health care. Baltimore; Johns Hopkins University Press: 1979.
  • 18. Cramer JA., Rosenheck R.Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv., 1998; 49: 196–201.
  • 19. Carrick JA. Medical ethics in the ancient world. Washington DC; Georgetown University Press: 2001.
  • 20. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care, 2004; 42: 200–209.
  • 21. Berg JS., Dischler J., Wagner DJ., Raia JJ., Palmer-Shevlin N.Medication compliance: a healthcare problem. Ann. Pharmacother., 1993; 27(9Suppl): S1–24.
  • 22. Takemoto SK., Pinsky BW., Schnitzler MA., Lentine KL., Willoughby LM., Burroughs TE., Bunnapradist S.A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am. J. Transplant., 2007; 7: 2704–2711.
  • 23. Young JL., Zonana HV., Shepler L.Medication noncompliance in schizophrenia: codification and update. Bull. Am. Acad. Psychiatry Law, 1986 ;14: 105–122.
  • 24. Fenton WS., Blyler CR., Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull., 1997; 23(4): 637–651.
  • 25. Lieberman JA., Stroup TS., McEvoy JP., Swartz MS., Rosenbeck RA., Perkins DO., Keefe RS., Davis SM., Davis CE., Lebowitz BD., Severe J., Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353: 1209–1223.
  • 26. Weiden P., Rapkin B., Zygmunt A., Mott T. , Goldman D., Frances A.Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr. Serv., 1995; 46(10): 1049–1054.
  • 27. McCombs JS., Nichol MB., Stimmel GL., Shi J., Smith RR. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J. Clin. Psychiatry, 1999; 60(suppl 19): 5–11.
  • 28. Docherty JP., Grogg AL., Kozma C. San Francisco; Calif: 2003. Antipsychotic partial compliance: impact on clinical outcomes in schizophrenia: In: Program and Abstracts of the 156th annual meeting of the American Psychiatric Association. May 17–22. Abstract NR172.
  • 29. Velligan DI., Lam F., Ereshefsky L., Miller AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr. Serv., 2003; 54: 665–667.
  • 30. Diaz E., Levine HB., Sullivan MC., Sernyak MJ., Hawkins KA., Cramer JA., Woods SW. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J. Psychiatry Neurosci., 2001; 26: 325–329.
  • 31. Shriqui CL. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Can. J. Psychiatry, 1995; 40: S38–48.
  • 32. Cramer JA., Mattson RH., Prevey ML., Scheyer RD., Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA, 1989; 261: 3273–3277.
  • 33. Tacchi M.-J., Scott J.Improving adherence in schizophrenia and bipolar disorders. Chichester, UK; John Wiley & Sons: 2005.
  • 34. Kampman O., Laippala P., Vaananen J., Koivisto E., Kiviniemi P., Kilkku N., Lehtinen K.Indicators of medication compliance in first-episode psychosis. Psychiatry Res., 2002; 110: 39–48.
  • 35. Lacro JP., Dunn LB., Dolder CR., Lecband SG., Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry, 2002; 63(10): 892–909.
  • 36. Coldham EL., Addington J., Addington D.Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr. Scand., 2002; 106: 286–290.
  • 37. Robinson DG., Woerner MG., Alvir JM., Bilder RM., Hinrichsen GA., Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res., 2002; 57: 209–219.
  • 38. Masand PS., Roca M., Turner MS., Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim. Care Companion J. Clin. Psychiatry, 2009; 11(4): 147–154.
  • 39. Aquila R., Weiden PJ., Emanuel M.Compliance and the rehabilitation alliance. J. Clin. Psychiatry, 1999; 60(suppl 19): 23–27.
  • 40. Karow A., Czekalla J., Dittmann RW., Schacht A., Wagner T., Lambert M., Schimmelmann BG., Naber D.Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J. Clin. Psychiatry, 2007; 68(1): 75–80.
  • 41. Elveva B., Maylor EA., Gilbert AL. Habitual prospective memory in schizophrenia. BMC Psychiatry, 2003; 3: 9.
  • 42. Jeste SD., Patterson TL., Palmer BW., Dolder CR., Goldman S., Jeste DV. Cognitive predictors of medication adherence among middle- aged and older outpatients with schizophrenia. Schizophr. Res., 2003; 63(1–2): 49–58.
  • 43. Narasimhan M., Pae CU., Masand N.Partial compliance with antipsychotics and its impact on patient outcomes. Int. J. Psych. Clin. Pract., 2007; 11: 102–111.
  • 44. Weiden PJ., Shaw E., Mann J.Causes of neuroleptic noncompliance. Psychiatr. Ann. 1986; 16: 571–575.
  • 45. Newcomer JW., Haupt DW. The metabolic effects of antipsychotic medications. Can. J. Psych., 2006; 51: 480–491.
  • 46. Berger A., Edelsberg J., Sanders KN., Alvir JM., Mychaskiw M., Oster G. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC Psychiatry, 2012; 12: 99.
  • 47. Dolder CR., Lacro JP., Dunn LB., Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am. J. Psychiatry, 2002; 159: 103–108.
  • 48. Diaz E., Neuse E., Sullivan MC., Pearsall HR., Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry, 2004; 65(3): 354–360.
  • 49. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin. Ther., 1984; 6(5): 592–599.
  • 50. Zhornitsky S., Stip E.Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr. Res. Treatment, 2012: Article ID 407171. doi:10.1155/2012/407171.
  • 51. Shi L., Ascher-Svanum H., Zhu B., Faries D., Montgomery W., Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr. Serv., 2007; 58: 482–488.
  • 52. Tattan TM., Creed FH. Negative symptoms of schizophrenia and compliance with medication. Schizophr. Bull., 2001; 27: 149–155.
  • 53. Kaplan G., Casoy J., Zummo J.Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer. Adherence, 2013; 7: 1171–1180.
  • 54. Dencker S.Neuroleptic relapse prevention guidelines for neuroleptic relapse prevention in schizophrenia. Berlin; Springer: 1991.
  • 55. Valenstein M., Copeland LA., Owen R., Blow FC., Vinic S.Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J. Clin. Psychiatry, 2001; 62(7): 545–551.
  • 56. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J. Clin. Psychiatry, 2006; 67(suppl 5): 9–14.
  • 57. Schmauss M., Sacchetti E., Kahn JP., Medori R.Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int. Clin. Psychopharmacol., 2007; 22: 85–92.
  • 58. Naber D., Karow A.Good tolerability equals good results: the patient’s perspective. Eur. Neuropsychopharmacol., 2001; 11(Suppl 4): S391–396.
  • 59. Jaeger M., Rossler W.Attitudes towards long-acting depot antipsychotics: a surveyof patients, relatives and psychiatrists. Psychiatry Res., 2010; 175: 58–62.
  • 60. Frank AF., Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch. Gen. Psychiatry, 1990; 47(3): 228–236.
  • 61. Hughes IH., Budd R.Compliance with antipsychotic medication: from theory to practice. J. Ment. Health, 1997; 6: 473–489.
  • 62. Klingberg S., Schneider S., Wittorf A., Buchkremer G., Wiedemann G. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors. Psychiatry Res., 2008; 161(2): 225–234.
  • 63. McEvoy JP., Freter S., Everett G., GellerJL., AppelbaumP., AppersonLJ., RothL.Insight and the clinical outcome of schizophrenic patients. J. Nerv. Ment. Dis., 1989; 177(1): 48–51.
  • 64. Kashner TM., Rader LE., Rodell DE., Beck CM., Rodell LR., Muller K.Family characteristics, substance abuse, and hospitalization patterns of patients with schizophrenia. Hosp. Community Psychiatry, 1991; 42: 195–197.
  • 65. Verdoux H., Lengronne J., Liraud F., Gonzales B., Assens F., Abalan F., van Os J.Medication adherence in psychosis: predictors and impact on outcome: a 2-year follow-up of first-admitted subjects. Acta Psychiatr. Scand., 2000; 102: 203–210.
  • 66. Gaebel W., Frick U., Kopcke W., Linden M., Muller P., Muller-Spahn F., Pietzcker A., Tegeler J.Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br. J. Psychiatry Suppl., 1993; 21: 8–12.
  • 67. Herz MI., Glazer WM., Mostert MA., Sheard MA., Szymanski HV., Hafez H., Mirza M., Vana J.Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch. Gen. Psychiatry, 1991; 48: 333–339.
  • 68. Carpenter W.Jr. Early, targeted pharmacotherapeutic intervention in schizophrenia. J. Clin. Psychiatry, 1986; 47(Suppl): 23–29.
  • 69. Carpenter WT. Jr. Maintenance therapy of persons with schizophrenia. J. Clin. Psychiatry, 1996; 57(Suppl 9): 10–18.
  • 70. Davis JM., Matalon L., Watanabe MD., Blake L., Matalon L.Depot antipsychotic drugs. Place in therapy. Drugs, 1994; 47: 741–773.
  • 71. Hui CL., Chen EY., Kan CS., Yip KC., Law CW., Chiu CP. Detection of non-adherent behaviour in early psychosis. Aust. N. Z. J.Psychiatry, 2006; 40: 446–451.
  • 72. Kamali M., Kelly BD., Clarke M., Browne S., Gevin M., Kinsella A., Lane A., Larkin C., O'Callaghan E.A prospective evaluation of adherence to medication in first episode schizophrenia. Eur. Psychiatry, 2006; 21: 29–33.
  • 73. Tandon R.In conclusion: does antipsychotic treatment modify the long-term course of schizophrenic illness? J. Psychiatr. Res., 1998; 32: 251–253.
  • 74. Robinson D., Woerner MG., Alvir JM., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman JA.. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry, 1999; 56: 241–247.
  • 75. Mojtabai R., Lavelle J., Gibson PJ., Sohler NL., Craig TJ., Carlson GA., Bromet EJ. Gaps in use of antipsychotics after discharge by first- admission patients with schizophrenia, 1989 to 1996. Psychiatr. Serv., 2002; 53: 337–339.
  • 76. Rabiner CJ., Wegner JT., Kane JM. Outcome study of first-episode psychosis. I: Relapse rates after 1 year. Am. J. Psychiatry, 1986; 143: 1155–1158.
  • 77. Steadman HJ., Mulvey EP., Monahan J., Robbins PC., Appelbaum PS., Grisso T., RothLH., SilverE.Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch. Gen. Psychiatry, 1998; 55: 393–401.
  • 78. Olfson M., Mechanic D., Hansell S., Boyer CA., Walkup J., Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr. Serv., 2000; 51: 216–222.
  • 79. Lieberman JA., Sheitman B., Chakos M., Robinson D., Schooler N., Keith S.The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J. Clin. Psychopharmacol., 1998; 18(2 suppl. 1): 20S–24S.
  • 80. Weiden PJ., Olfson M.Cost of relapse in schizophrenia. Schizophr. Bull., 1995; 21: 419–429.
  • 81. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol. Psychiatry, 1999; 46: 899–907.
  • 82. Keith SJ., Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J. Clin. Psychiatry, 2003; 64: 1308–1315.
  • 83. Valenstein M., Ganoczy D., McCarthy JF., Myra Kim H., Lee TA., Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J. Clin. Psychiatry, 2006; 67: 1542–1550.
  • 84. Perkins DO. Adherence to antipsychotic medications. J. Clin. Psychiatry, 1999; 60(Suppl 21): 25–30.
  • 85. Docherty J., Mahmoud R., Grogg A., Kozma C.Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. In: 9th International Congress on Schizophrenia Research; 29 March – 02 April2003, Colarado Springs, Colorado. 2003; 60(1): 281–282.
  • 86. Valenstein M., Copeland LA., Blow FC., McCarthy JF., Zeber JE., Gillon L., Bringham CR., Stavenger T.Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med. Care, 2002; 40: 630–639.
  • 87. Gilmer TP., Dolder CR., Lacro JP., Folsom DP., Lindamer L., Garcia P., Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry, 2004; 161: 692–699.
  • 88. Swett C.Symptom severity and number of previous psychiatric admissions as predictors of readmission. Psychiatr. Serv., 1995; 46 (5): 482–485.
  • 89. Chen EY., Hui CL., Dunn EL., Miao MY., Yeung WS., Wong CK., Chan WF., Tang WN. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr. Res., 2005; 77(1): 99–104.
  • 90. Robinson DG., Woerner MG., Delman HM., Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr. Bull., 2005; 31(3): 705–722.
  • 91. Gitlin M., Nuechterlein K., Subotnik KL., Ventura J., Mintz J., Fogelson DL., Bartzokis G., AravagiriM.Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am. J. Psychiatry, 2001; 158(11): 1835–1842.
  • 92. Tiihonen J., Haukka J., Taylor M., Haddad PM., Patel MX., Korhonen P.A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry, 2011; 168(6): 603–609.
  • 93. Liu-Seifert H., Osuntokun O., Feldman P.Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr. Psychiatry, 2012; 53: 107–115.
  • 94. Misdrahi D., Petit M., Blanc O., Bayle F., Llorca PM. The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nord. J. Psychiatry, 2012; 66(1): 49–54.
  • 95. Markowitz M., Karve S., Panish J., Candrilli SD., Alphs L.Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry, 2013; 13: 246.
  • 96. Vassileva I., Milanova V., Asan T.Predictors of medication non- adherence in Bulgarian outpatients with schizophrenia. Community Ment. Health J., 2014 Jan 23.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-2081-3910-2014-15-1-7
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.